Ashley Roberts, a consultant to the Calorie Control Council, a food-industry trade group that promotes the use of aspartame and other artificial sweeteners, (https://caloriecontrol.org/about-the-council/) makes several incorrect and unsubstantiated claims in his response to our recent commentary, “Aspartame and Cancer – New Evidence for Causation” [1].

Our commentary discussed the significance of a report by Tibaldi et al. (2020) who reexamined lesions from Ramazzini Institute (RI) studies of rodents exposed to aspartame [2]. Those RI studies had reported that aspartame causes dose-related increases in malignant lesions in multiple organs in rats and mice [3–5]. The studies reported additionally that prenatal aspartame exposures caused increased cancers in offspring at lower doses than in adults [4], a finding of serious concern for public health given the extensive consumption of low-calorie, aspartame-sweetened beverages by pregnant women. The goal of the study by Tibaldi et al. was to evaluate the accuracy of the RI’s diagnoses of malignancy.

Tibaldi et al’s reevaluation included both immunohistochemical and morphological examinations of the rodent lesions. The premise underlying immunohistochemical analysis is that all cells in a malignant lesion are expected to be immunohistochemically identical - i.e., monoclonal – because they are all the direct descendants of a single transformed cell [6, 7]. By contrast, the inflammatory lymphocytes that respond to an infection are of diverse cellular origin. They are therefore not immunohistochemically identical, and instead are polyclonal. Tibaldi et al’s immunohistochemical analysis employed a battery of nine markers: Ki67, CD3, PAX5, CD20, CD68, TdT, CD45, CD14 and CD33.

Tibaldi et al confirmed that 72 of the 78 lesions originally diagnosed by RI as malignant were, in fact, monoclonal. Tibaldi et al. thus confirmed the original RI diagnoses of malignancy in 92.3% of the aspartame-exposed rodents [2].

Roberts’ critique is based on his review of the histological slides presented by Tibaldi et al. and on the unsubstantiated and previously refuted [8, 9] claim that there was infection in the RI laboratories that caused inflammatory lesions in the experimental animals. He ignores Tibaldi et al’s immunohistochemical findings and does not attempt to rebut them.

Roberts also fails to acknowledge, rebut or offer any alternative explanation for the dose-response relationship between aspartame dose and cancer incidence that was clearly evident in the RI studies and was confirmed by Tibaldi et al. Increasing aspartame exposures were associated with statistically significant increases in incidence of all hematolymphatic malignancies ($p = 0.006$), including both lymphomas ($p = 0.032$) and leukemias ($p = 0.031$) [2]. Infection would seem an unlikely explanation for such a trend.

Likewise, Roberts fails to acknowledge, rebut or explain away the RI finding that prenatal exposures to aspartame caused increased malignancies in offspring at lower doses than in adults [4]. Again, Infection would seem an unlikely explanation for this finding.
In summary, we find Robert’s critique to be flawed and unconvincing. We therefore reiterate our conclusion that national and international public health agencies need to follow the example of the International Agency for Research on Cancer (IARC) [9] and take careful notice of these new data on the carcinogenicity of aspartame [2]. These agencies need to pay particular heed to the potential of lower-dose aspartame exposures during pregnancy to cause increased incidence of leukemia and lymphoma in offspring [4].

Facile dismissals of the carcinogenicity of aspartame put forth by vested interests can no longer be sustained. Such unsubstantiated claims can impede public health interventions and can lead to unnecessary cancers, including childhood cancers and premature deaths.

Acknowledgements
The authors acknowledge the invaluable contributions to cancer biology and prevention of Drs. Cesare Maltoni, Morando Soffritti and Fiorella Belpoggi of the Ramazzini Institute.

Authors’ contributions
Both authors contributed to the conceptualization, writing and editing of the manuscript. The author(s) read and approved the final manuscript.

Funding
None.

Availability of data and materials
Not applicable.

Declarations

Ethics approval and consent to participate
Not applicable

Consent for publication
Not applicable

Competing interests
Drs. Landrigan and Straif are both unpaid members of the International Scientific Advisory Board of the Ramazzini Institute.

Received: 6 September 2021 Accepted: 7 September 2021 Published online: 21 September 2021

References
1. Landrigan PJ, Straif K. Aspartame and cancer – new evidence causation. Environ Health. 2021;20(1):42. https://doi.org/10.1186/s12940-021-00725-y.
2. Tibaldi E, Gnudi F, Panzacchi S, Mandrioli D, Vornoli A, Manservigi M, Sargi D, Falciuni L, Buia L, Belpoggi F. Identification of aspartame-induced haematopoietic and lymphoid tumours in rats after lifetime treatment. Acta Histochem. 2020;122:15148. https://doi.org/10.1016/j.acthis.2020.151548.
3. Belpoggi F, Soffritti M, Padovani M, Degli Esposti D, Lauriola M, Minardi F. Results of long-term carcinogenicity bioassay on Sprague-Dawley rats exposed to aspartame administered in feed. Ann NY Acad Sci. 2006;1076:559–77. https://doi.org/10.1196/annals.1371.080.
4. Soffritti M, Belpoggi F, Tibaldi E, Degli Esposti D, Lauriola M. Lifetime exposure to low doses of aspartame beginning during prenatal life increases Cancer effects in rats. Environ Health Perspect. 2007;115(9):1293–7. https://doi.org/10.1289/ehp.10271.
5. Soffritti M, Belpoggi F, Manservigi M, Tibaldi E, Lauriola M, Falciuni L, Buia L. Aspartame administered in feed, beginning prenatally through life span, induces cancers of the liver and lung in male Swiss mice. Am J Ind Med. 2010;53:1197–206. https://doi.org/10.1002/ajim.20896.
6. van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocol for detection of clonal immunoglobulin and T cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98–1936. Leukaemia. 2003;17(12):2257–317. https://doi.org/10.1038/sj.leu.2403202.
7. Gift JS, Caldwell JC, Jinot J, Evans MV, Cote I, Vandenberg JJ. Scientific considerations for evaluating cancer bioassays conducted by the Ramazzini institute. Environ Health Perspect. 2013;121:1253–63. https://doi.org/10.1289/ehp.1306661.
8. Caldwell JC, Jinot J, DeVoney D, Gift JS. Evaluation of evidence for infection as a mode of action for induction of rat lymphoma. Environ Mol Mutagen. 2008;49(2):155–64. https://doi.org/10.1002/em.20356.
9. IARC (International Agency for Research on Cancer). IARC Monographs Priorities Group. Advisory Group. Recommendations on priorities for the IARC Monographs. Lancet Oncol. 2019;20(8):763–4. https://doi.org/10.1016/S1470-2245(19)30246-3.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.